100 reports of this reaction
2.2% of all MITOMYCIN reports
#10 most reported adverse reaction
PANCYTOPENIA is the #10 most commonly reported adverse reaction for MITOMYCIN, manufactured by UroGen Pharma, Inc.. There are 100 FDA adverse event reports linking MITOMYCIN to PANCYTOPENIA. This represents approximately 2.2% of all 4,566 adverse event reports for this drug.
Patients taking MITOMYCIN who experience pancytopenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PANCYTOPENIA is a less commonly reported adverse event for MITOMYCIN, but still significant enough to appear in the safety profile.
In addition to pancytopenia, the following adverse reactions have been reported for MITOMYCIN:
The following drugs have also been linked to pancytopenia in FDA adverse event reports:
PANCYTOPENIA has been reported as an adverse event in 100 FDA reports for MITOMYCIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
PANCYTOPENIA accounts for approximately 2.2% of all adverse event reports for MITOMYCIN, making it a notable side effect.
If you experience pancytopenia while taking MITOMYCIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.